Stem cells have been holding great promise for regenerative medicine for years. In the last decade, several studies have shown that this type of cell, which in Spanish is called mother cell because of its ability to give rise to a variety of different cell types, can be applied in regenerative medicine for diseases such as muscular and nervous system disorders, among others. Researchers and stem cell pioneers Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea. However, one of the main limitations in the application of these cell therapies is the quality of the stem cells that can be generated in the laboratory, which impedes their use for therapeutic purposes.Now, a team from the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), led by researcher Marcos Malumbres, has developed a new, simple and fast technology that enhances in vitro and in vivo the potential of stem cells to differentiate into adult cells. The research results are published in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have. The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types, says Mara Salazar-Roa, researcher at the CNIO, first author of the article and co-corresponding author.

In this study, the researchers identified an RNA sequence, called microRNA 203, which is found in the earliest embryonic stages before the embryo implants in the womb and when stem cells still have their maximum capacity to generate all the different tissues. When they added this molecule to stem cells in the laboratory, they discovered that the cells ability to convert to other cell types improved significantly.

To corroborate this, they used stem cells of human and murine origin, and of genetically modified mice. The results were spectacular, both in mouse cells and in human cells. Application of this microRNA for just 5 days boosts the potential of stem cells in all scenarios we tested and improves their ability to become other specialised cells, even months after having been in contact with the microRNA, says Salazar-Roa.

According to the study, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the door to an improved generation of different cell types necessary for the treatment of degenerative diseases.

Malumbres, head of the CNIO Cell and Cancer Division Group, says: To bring this asset to the clinic, collaboration with laboratories or companies that want to exploit this technology is now necessary in each specific case. In this context, Salazar-Roa recently participated, in close collaboration with the CNIOs Innovation team, in prestigious innovation programs such as IDEA2 Global of the Massachusetts Institute of Technology (MIT) and CaixaImpulse of the la Caixa Foundation, from which they also obtained funding to start the development of this technology.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells - Technology Networks

A recent report published by QMI on mesenchymal stem cells market is a detailed assessment of the most important market dynamics. After carrying out a thorough research of mesenchymal stem cells market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for mesenchymal stem cells during the forecast period. It can enable manufacturers of mesenchymal stem cells to change their production and marketing strategies in order to envisage maximum growth.

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-61514?utm_source=3WN&utm_medium=santosh

According to the report, the mesenchymal stem cells market has been segmented by source (bone marrow, umbilical cord blood, peripheral blood, lung tissue, synovial tissues, amniotic fluids, adipose tissues), by application (injuries, drug discovery, cardiovascular infraction, others).Insights about the regional distribution of market:The market has been segmented in major regions to understand the global development and demand patterns of this market.

For the mesenchymal stem cells market, the segments by region are North America, Asia Pacific, Western Europe, Eastern Europe, Middle East, and Rest of the World. During the forecast period, North America, Asia Pacific and Western Europe are expected to be major regions on the mesenchymal stem cells market.

North America and Western Europe have been one of the key regions as they have an established healthcare infrastructure for product innovations and early adaptations. This is estimated to drive demand for the mesenchymal stem cells market in these regions. In addition to this, some of the major companies operating in this market are headquartered in these regions.

Asia Pacific is estimated to register a high CAGR mesenchymal stem cells market. The APAC region has witnessed strategic investments by global companies to cater to the growing demand for healthcare solutions in recent years. The Middle East and Rest of the World are estimated to be emerging regions for the mesenchymal stem cells market.

Make An Inquiry For Purchasing This Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61514?utm_source=3WN&utm_medium=santosh

Market Players Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem Cell Technologies Inc., Celprogen, Inc.

Reasons to Buy This Report:o It provides niche insights for a decision about every possible segment helping in the strategic decision-making process.o Market size estimation of the mesenchymal stem cells market on a regional and global basis.

o A unique research design for market size estimation and forecast.o Identification of major companies operating in the market with related developmentso Exhaustive scope to cover all the possible segments helping every stakeholder in the mesenchymal stem cells market.

Market Segmentation:By Source:o Bone Marrowo Umbilical Cord Bloodo Peripheral Bloodo Lung Tissueo Synovial Tissueso Amniotic Fluidso Adipose Tissues

By Application:o Injurieso Drug Discoveryo Cardiovascular Infractiono Others

By Region:o North Americao North America, by Country? US? Canada? Mexicoo North America, by Sourceo North America, by Application

o Western Europeo Western Europe, by Country? Germany? UK? France? Italy? Spain? The Netherlands? Rest of Western Europeo Western Europe, by Sourceo Western Europe, by Application

o Asia Pacifico Asia Pacific, by Country? China? India? Japan? South Korea? Australia? Indonesia? Rest of Asia Pacifico Asia Pacific, by Sourceo Asia Pacific, by Application

o Eastern Europeo Eastern Europe, by Country? Russia? Turkey? Rest of Eastern Europeo Eastern Europe, by Sourceo Eastern Europe, by Application

o Middle Easto Middle East, by Country? UAE? Saudi Arabia? Qatar? Iran? Rest of Middle Easto Middle East, by Sourceo Middle East, by Applicationo Rest of the Worldo Rest of the World, by Country? South America? Africao Rest of the World, by Sourceo Rest of the World, by Application

Years Covered in the Study:Historic Year: 2016-2017Base Year: 2018Estimated Year: 2019Forecast Year: 2028

Objectives of this report:o To estimate the market size for mesenchymal stem cells market on a regional and global basis.o To identify major segments in mesenchymal stem cells market and evaluate their market shares and demand.

o To provide a competitive scenario for the mesenchymal stem cells market with major developments observed by key companies in the historic years.o To evaluate key factors governing the dynamics of mesenchymal stem cells market with their potential gravity during the forecast period.Customization:This study is customized to meet your specific requirements:

o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: +91 706 672 4848 +1 208 405 2835 / +44 121 364 6144 /Email: [emailprotected]Web:www.quincemarketinsights.com

ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Original post:
Impacts of the COVID-19-Mesenchymal Stem Cells Market Size Current and Future Industry Trends, 2020-2028 - 3rd Watch News

The global artificial blood substitutes market is predicted to register stellar growth rate in the forthcoming years. The presence of a large patient population that requires blood transfusion during surgeries, trauma, and for other blood disorders, which remains unmet due to shortage of blood supply has necessitated creation of artificial blood substitutes.

Artificial blood substitutes are primarily used to mimic oxygen carrying capacity of biological blood and expand the blood volume in the human body. Use of artificial blood substitutes is at present considered an alternate method for blood transfusion. Further research is underway to develop more alternate methods for blood transfusion, including developing human red blood cells (RBCs) from stem cells of donors blood.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5793

The research report provides an in-depth analysis of the artificial blood substitutes market over the forecast period. The report covers each and every key aspect pertinent to the market, including market dynamics, segmentation, and competitive scenario. The assessment of artificial blood substitutes market presented herein could serve as a valuable guide for both existing market participants, and the ones seeking entry in this market.

Artificial Blood Substitutes Market: Competitive Landscape and Notable Developments

The initial clinical trials for blood substitutes are recorded as early as early 1600, wherein milk, beer, urine, sheeps blood, and perfluorochemicals were administered as blood substitutes for animal and human subjects.

In successive periods, clinical trials of milk transfusion, including goats milk in large quantities were carried out but in vain. Clinical trials also involved injecting human milk that were futile too, which led researchers concede human milk not to be a substitute for blood.

With continual extensive research, over long periods, scientists have attained some success to develop blood substitutes. Artificial blood thus far developed can substitute red blood cells. While biological human blood performs several different functions, artificial blood performs the sole purpose of transporting oxygen and carbon dioxide in the body.

Established biotechnology companies in the ambit are engaged to develop blood substitutes. Such pursuits primarily involve developing oxygen carriers similar or above the capacity of biological blood. With concerted efforts of some top-notch biotechnology companies, namely HEMARINA SA, KaloCyte Inc. and Hemoglobin Oxygen Therapeutics LLC blood substitutes are available as oxygen carrier based on hemoglobin and perfluorocarbon-based oxygen carrier.

Nevertheless, presence of several well-established biotechnology companies engaged in the development of blood substitutes portrays a competitive yet moderately consolidated vendor landscape of the artificial blood substitutes market.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=5793&ltype=S

Artificial Blood Substitutes Market: Key Trends

Worldwide, excessive blood loss due to traumatic injuries and diseases is responsible for vast number of deaths every year. Limited availability of fresh blood and small storage periods of fresh blood for such situations have necessitated development of artificial blood substitutes.

With continual experiments over long periods, scientists have thus far been able to create substitutes to mimic oxygen carrier capacity of biological blood. Development of perfluorochemical-based oxygen carrier and hemoglobin-based oxygen carrier and provide thrust to the artificial blood substitutes market.

Besides this, advent of stem cell therapy is poised to create new opportunities for demand of artificial blood substitutes.

However, on the downside, lower shelf life of artificial blood products and stringent regulatory approval process for these products restrain the growth of artificial blood substitutes market.

Artificial Blood Substitutes Market: Regional Outlook

North America is at the fore for demand within overall artificial blood substitutes market. Presence of advanced healthcare combined with awareness of individuals for alternate demonstrated therapies account for leading revenue share of the region.

Continual advances in stem cell therapy further indicates sustained growth of artificial blood substitutes market in the region.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5793

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read the original:
Artificial Blood Substitutes Market - Insights into how contours of market will change in coming years - BioSpace

Global Stem Cells Cryopreservation Equipments Market: Competitive Analysis

The latest report on the globalStem Cells Cryopreservation Equipments marketpublished by theMarket Data Analyticsprovides a comprehensive study of the Stem Cells Cryopreservation Equipments market. This research study includes historical data from 2015-2018 and the forecast from 2019 to 2026. The Stem Cells Cryopreservation Equipments report covers the latest impact ofCOVID-19on the Stem Cells Cryopreservation Equipments market. The pandemic has affected every market around the globe in a negative way. As the world still struggles to recover from the COVID-19 situation it will take a long time for every market to recover its losses. The latest report on the global Stem Cells Cryopreservation Equipments market provides you with each and every details about the Stem Cells Cryopreservation Equipments market, that is, the current and the future market scenario along with how it was in the past few years.

Request a sample copy of this report::https://www.marketdataanalytics.biz/worldwide-stem-cells-cryopreservation-equipments-market-report-2020-industry-37765.html#request-sample

As per our research analysts the impact of COVID-19 has strongly affected the future market opportunities, revenue growth graph, and the profit gains of the business. The report on the global Stem Cells Cryopreservation Equipments market consists of more than 25 tables and above 30 figures. The complete report includes more than 150 pages and is available in PDF format.

The research on the Stem Cells Cryopreservation Equipments market includes the latest opinions of the market experts as to how the market has been affected by COVID-19 and how the market scenario has changed in the past four months. The research analysts have done a thorough research and have achieved the latest market numbers and the compound annual growth rate.

Read Full Research Report@https://www.marketdataanalytics.biz/worldwide-stem-cells-cryopreservation-equipments-market-report-2020-industry-37765.html

The report details are segregated into the market overview, scope of the market, research methodologies used, market drivers, restraints, opportunities, and challenges. The other quantitative and qualitative data includes the market segmentation, regional bifurcation, and the profiling of the industry players.

The market is segmented into{Liquid Phase, Vapor Phase};{Cord Blood Stem Cells Cryopreservation, Other Stem Cells Cryopreservation}. The geographical presence of the Stem Cells Cryopreservation Equipments market is categorized mainly into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Some of the major industry players included within the Stem Cells Cryopreservation Equipments market study includesChart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol,.

The data provided in the global Stem Cells Cryopreservation Equipments market is highly accurate and reliable thus enabling the client to better understand the current market size and position.

If Any Inquiry of Stem Cells Cryopreservation Equipments Report:https://www.marketdataanalytics.biz/worldwide-stem-cells-cryopreservation-equipments-market-report-2020-industry-37765.html#inquiry-for-buying

Benefits of Buying this Market Research Report:

1.Analyst advocacy:Get correct answers of your queries from our analysts team of experts before and after purchasing the report.2.Meet Customers Requirements:Our expert team will assist with all your research requirements and customize the report.3.Unique Expertise:We centre around the quality standards and reliability of the report.4.One of a kind Expertise:Experts will give splendid bits of knowledge about the report.

Read more from the original source:
Global Stem Cells Cryopreservation Equipments Market with Coronavirus (COVID-19) Impact Analysis | likewise Industry is Booming Globaly with Top...

No matter how many molecules he threw at them, Paul Tesar couldnt get the brain cells to survive. Or he got them to survive, but then to everyones bafflement they still couldnt do what they were supposed to.

Tesar, a professor of innovative therapeutics at Case Western University, had spent years building stem cell models for multiple sclerosis, growing brain organoids in dishes and then seeing what small molecules restored myelin production. Now he was trying to do the same for other myelin diseases, particularly an ultra-rare genetic condition called Pelizaeus-Merzbacher disease, where a single mutation leads to the death of the myelin-producing neurons, called oligodendrocytes, and can kill patients in infancy.

Weve screened many thousands of small molecule compounds, Tesar toldEndpoints News. But we could not get them to restore function.

Then Tesar got an email from Ionis, the California biotech that had just used an RNA-modifying technology called antisense to build Spinraza, the first FDA-approved drug for the genetic neurological disorder spinal muscular atrophy.

Now, in a study published inNature,Tesar and Ionis have shown they can use a single dose of drug built from that technology to keep those neurons both alive and well-functioning and treat the disease at least in mice. The publication isnt groundbreaking, antisense researchers say, but it shows for the first time that antisense can be used to effectively target oligodendrocytes, an insight its authors hope will open up other rare myelin disorders to therapy.

Its not that its different than everything thats been done before, but it goes further than everything thats gone before, Jon Watts, a professor at the RNA Therapeutics Institute at UMass Medical School who is not affiliated with Ionis or the paper, told Endpoints, both in terms of duration of effect after a single dose, and the real focus in getting the biology, the therapeutic effect in oligodendrocytes.

The applicability to the most famous and common of myelin disorders, multiple sclerosis, is limited, researchers say, both because the therapy relied on having a specific gene to target and because the paper doesnt prove you can get an effect on the peripheral nervous system. Still, Berit Powers, an assistant director at Ioniss neurology research department and a co-author, pointed to several other genetic myelin disorders, known as leukodystrophies. That includes an Ionis program on Alexander disease, a rare childhood condition with Parkinsons-like symptoms.

Were certainly exploring the potential of ASOs in non-monogenic conditions like MS, Powers told Endpoints, using a shorthand for antisense oligonucleotides. But that work is very new.

This is hardly Tesars first foray into biotech. In 2015, he showed in Naturehow certain small molecules could regenerate myelin the holy grail for an MS therapy and founded Convelo Therapeutics around that work. Last year, they partnered with Genentech for an undisclosed sum and an exclusive option to acquire the company.

Myelin is a fatty substance that coats neurons, insulating them and helping electric currents pass through. Tesars lab was broadly interested in the question of why myelin fails, both in MS and rare diseases, and about 7 years ago he got a grant to work from the PMD Foundation.

First, Tesar built stem cell models of the disease, figuring out how different mutations in a single gene, called PLP1, lead oligodendrocyte progenitor cells (the stem cell-like cells that will become oligodendrocytes) to create a toxic RNA and a mutated protein that kills them soon after they differentiate. Then, he tried to suppress that gene with different chemicals, eventually testing over 3,000 different compounds.

He was able to eventually get the oligodendrocytes to survive, but to his surprise, they didnt produce myelin as they should. The surviving cells still couldnt properly function, revealing, he wrote in a 2018 Cell paper a second phase of pathology. A hypothetical treatment, he argued, would have to both keep progenitor cells alive and then treat the survivors in a way that induces myelination.

With antisense, he and Powers Ionis team were able to do both. Antisense oligonucelotides consist of strands of RNA that are a mirror image of the RNA you want to target. The mirror binds to and silences, or turns off, that gene. In the study, the researchers confirmed that PLP1 was disease-causing by knocking out the gene in cell lines with CRISPR. Then they injected mice with antisense strands through the spinal cord, the same way Spinraza is delivered. (You cant use CRISPR to treat the disease in humans, because theres no good way yet of delivering it.)

Powers and Tesar were unsure if they would be able to target oligodendrocytes and progenitor cells. What they found, though, was complete restoration of oligodendrocytes and a profound rescue of neurological function. Myelin, too, was finally restored. Mice that died after 3 weeks now lived for over 200 days.

Ionis hasnt licensed the drug and its unclear yet the implications for other diseases, but researchers say the results could translate into humans quickly, at least by drug development standards.

I do think its very rapidly translatable, Watts said. Based on the data theyre showing here, and based on the unmet need, this appears to be something that could be translated pretty quickly into a Phase I trial.

Excerpt from:
Ionis, leading MS researcher throw antisense at a new type of brain cells - Endpoints News

Stem Cells Cryopreservation Equipments Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

TheStem Cells Cryopreservation Equipments marketreport begins with the market overview/market definition and the market scope. This helps in understanding what exactly is the report study dealing with. The next section includes the target audience of the Stem Cells Cryopreservation Equipments market. It is very important for the clients to understand what type of users or what kind of consumers deal with Stem Cells Cryopreservation Equipments market in order to determine their focus goals.

Request Free Sample Copy of Stem Cells Cryopreservation Equipments Market Research Report@http://www.marketresearchstore.com/report/global-stem-cells-cryopreservation-equipments-market-report-2019-528068#RequestSample

In the last section, the Stem Cells Cryopreservation Equipments market report incorporates detailed information on the demand & supply chain analysis, import and export, industry size, sales volume, market shares, as well as value analysis of all the industry players operating in the Stem Cells Cryopreservation Equipments market. Some of the major market players that are included areChart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beol, . Each market player is profiles in detail within the report by the research analysts.

In the next section, the Stem Cells Cryopreservation Equipments market report includes the research tools and methodologies that were incorporated while studying the Stem Cells Cryopreservation Equipments market. For instance, Porters Five Force analysis, SWOT analysis, PESTLE analysis, top-down or the bottom-up approach that was used for market data analysis. It also includes details about the primary research and the secondary research that were conducted by the research analysts.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-stem-cells-cryopreservation-equipments-market-report-2019-528068

The next major section of the Stem Cells Cryopreservation Equipments market study includes the market segmentation. To understand any market with ease the market is segregated into segments, such as its product type, application, technology, end-use industry. By dividing the market into small components helps in understanding the market with more clarity. The market segments of the Stem Cells Cryopreservation Equipments market includes{Liquid Phase, Vapor Phase}; {Cord Blood Stem Cells Cryopreservation, Other Stem Cells Cryopreservation}. The data that is provided within the study is both quantitative and qualitative. Data is represented with the help of tables and figures that include graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc.

Another major segment of the Stem Cells Cryopreservation Equipments market is its geographical presence on the global platform. The major regions that have been considered include Asia Pacific, Europe, Latin America, North America, and the Middle East and Africa. The Stem Cells Cryopreservation Equipments market study is not restricted to regional level but also includes country-wise data.

If Any Inquiry of Stem Cells Cryopreservation Equipments Report:http://www.marketresearchstore.com/report/global-stem-cells-cryopreservation-equipments-market-report-2019-528068#InquiryForBuying

Major Advantages for Stem Cells Cryopreservation Equipments Market:

Well-organized description of the international Stem Cells Cryopreservation Equipments market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Stem Cells Cryopreservation Equipments industry. The Stem Cells Cryopreservation Equipments market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Stem Cells Cryopreservation Equipments market. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

Read more here:
Global Stem Cells Cryopreservation Equipments Market with COVID-19 After Effects Analysis by Key Players | Chart, Worthington Industries, Cesca...